Charles River Laboratories International, Inc. $CRL Holdings Reduced by Gotham Asset Management LLC

Gotham Asset Management LLC lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 8.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 289,516 shares of the medical research company’s stock after selling 26,239 shares during the quarter. Gotham Asset Management LLC owned about 0.59% of Charles River Laboratories International worth $57,753,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Jones Financial Companies Lllp increased its position in Charles River Laboratories International by 167.6% in the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock valued at $253,000 after acquiring an additional 1,074 shares during the period. Empowered Funds LLC acquired a new position in Charles River Laboratories International during the 1st quarter worth $418,000. American Century Companies Inc. grew its stake in shares of Charles River Laboratories International by 41.9% in the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after purchasing an additional 1,616 shares in the last quarter. Brown Advisory Inc. grew its stake in shares of Charles River Laboratories International by 5.1% in the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after purchasing an additional 114 shares in the last quarter. Finally, California Public Employees Retirement System increased its holdings in shares of Charles River Laboratories International by 3.9% during the second quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock valued at $12,837,000 after purchasing an additional 3,198 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Morgan Stanley upgraded shares of Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $185.00 to $220.00 in a research report on Wednesday. TD Cowen dropped their price target on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Mizuho set a $192.00 price objective on shares of Charles River Laboratories International in a report on Friday, May 8th. Barclays boosted their target price on Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, Royal Bank Of Canada started coverage on Charles River Laboratories International in a research report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 target price for the company. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $211.00.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $182.97 on Thursday. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. The company has a 50-day moving average of $174.31 and a 200-day moving average of $182.64. Charles River Laboratories International, Inc. has a twelve month low of $143.06 and a twelve month high of $228.88. The firm has a market cap of $8.81 billion, a price-to-earnings ratio of -48.66, a price-to-earnings-growth ratio of 2.11 and a beta of 1.46.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.96 by $0.10. The business had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Analysts forecast that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.